ASND vs. TEM: Ascendis Pharma vs. Tempus AI Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Ascendis Pharma (ASND) has been public since January 28, 2015, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Ascendis Pharma (ASND) is defensive at 0.38 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Ascendis Pharma (ASND) reports 70.85%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Ascendis Pharma (ASND) reports 64.98%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Ascendis Pharma (ASND) at 98.03% and Tempus AI (TEM) at 83.41% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.

Neither Ascendis Pharma (ASND) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Ascendis Pharma (ASND) at 2.99 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Ascendis Pharma (ASND) at 0.31 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Ascendis Pharma (ASND) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Ascendis Pharma (ASND) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: Ascendis Pharma (ASND) at 10.45 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.

Valuation Metrics